Compare ACHR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | APGE |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | 1660 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | ACHR | APGE |
|---|---|---|
| Price | $5.09 | $88.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $12.00 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 51.6M | 962.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4,986.67 | N/A |
| Revenue Next Year | $876.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $34.34 |
| 52 Week High | $14.62 | $95.32 |
| Indicator | ACHR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 55.81 |
| Support Level | $4.80 | $73.70 |
| Resistance Level | $7.40 | $91.83 |
| Average True Range (ATR) | 0.44 | 5.41 |
| MACD | -0.17 | 0.72 |
| Stochastic Oscillator | 7.64 | 74.81 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.